Targeting Metabolic Reprogramming in Acute Myeloid Leukemia

Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions

(2019) Katharina Rothe et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia

(2019) Nicolas Chapuis et al.   Frontiers in Oncology

Targeting Glutamine Metabolism for Cancer Treatment

(2018) Yeon-Kyung Choi et al.   Biomolecules & Therapeutics

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML

(2018) Lauren Herschbein et al.   BLOOD REVIEWS

As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid

(2018) Natalya N. Pavlova et al.   Cell Metabolism

Asparagine and Glutamine: Co-conspirators Fueling Metastasis

(2018) Ming Luo et al.   Cell Metabolism

The role of AMPK/mTOR modulators in therapy of acute myeloid leukemia

(2018) Dora Visnjic et al.   CURRENT MEDICINAL CHEMISTRY

Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia

(2018) Mark A. Gregory et al.   EXPERIMENTAL HEMATOLOGY

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia

(2018) S. Rudat et al.   LEUKEMIA

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

(2018) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy

(2018) Jing Jin et al.   Oxidative Medicine and Cellular Longevity

A concise review of BCL-2 inhibition in acute myeloid leukemia

(2018) Meera Yogarajah et al.   Expert Review of Hematology

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

(2018) Yann Ferret et al.   HAEMATOLOGICA

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2

(2018) Amir T. Fathi et al.   JAMA Oncology

Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells

(2018) Haobin Ye et al.   CANCER CELL

Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells

(2018) Olga Pereira et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Acute myeloid leukemia: 2019 update on risk-stratification and management

(2018) Elihu H. Estey   AMERICAN JOURNAL OF HEMATOLOGY

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

(2018) Courtney L. Jones et al.   CANCER CELL

Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia

(2018) Lucille Stuani et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia

(2017) Yoko Tabe et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Acute myeloid leukemia stem cell function is preserved in the absence of autophagy

(2017) Amy H. Porter et al.   HAEMATOLOGICA

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells

(2017) L Poulain et al.   LEUKEMIA

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia

(2017) Q Heydt et al.   ONCOGENE

Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia

(2017) Hendrik Folkerts et al.   Cell Death & Disease

Glutamine metabolism regulates autophagy-dependent mTORC1 reactivation during amino acid starvation

(2017) Hayden Weng Siong Tan et al.   Nature Communications

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

(2017) Katharine Yen et al.   Cancer Discovery

Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer

(2017) Jiaqiu Li et al.   Oncotarget

Acute myeloid leukemia stem cell function is preserved in the absence of autophagy

(2017) Amy H. Porter et al.   HAEMATOLOGICA

Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism

(2017) Balaraman Kalyanaraman   Redox Biology

IDH mutations in cancer and progress toward development of targeted therapeutics

(2016) L. Dang et al.   ANNALS OF ONCOLOGY

Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia

(2016) Sujan Piya et al.   Autophagy

Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia

(2016) S. Piya et al.   BLOOD

Autophagy, a key mechanism of oncogenesis and resistance in leukemia

(2016) Patrick Auberger et al.   BLOOD

Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia

(2016) Y. Sumitomo et al.   BLOOD

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression

(2016) T.-C. Ho et al.   BLOOD

Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation

(2016) Amin Huang et al.   CANCER LETTERS

Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche

(2016) Haobin Ye et al.   Cell Stem Cell

Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

(2016) Heidi D. Klepin   CLINICS IN GERIATRIC MEDICINE

Targeting the mTOR Pathway in Leukemia

(2016) Shira Dinner et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms

(2016) V Visconte et al.   LEUKEMIA

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia

(2016) M Kontro et al.   LEUKEMIA

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Warburg Effect: How Does it Benefit Cancer Cells?

(2016) Maria V. Liberti et al.   TRENDS IN BIOCHEMICAL SCIENCES

Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model

(2016) Qiang Liu et al.   Cell Death & Disease

Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia

(2016) KUI SONG et al.   Oncology Letters

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes

(2016) Polina Matre et al.   Oncotarget

Fundamentals of cancer metabolism

(2016) R. J. DeBerardinis et al.   Science Advances

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

(2016) Jinlong Shi et al.   EBioMedicine

Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells

(2015) Yan Wu et al.   APOPTOSIS

Targeting leukemia's "fatty tooth"

(2015) I. Samudio et al.   BLOOD

Azacitidine in AML: a treatment option?

(2015) G. Huls   BLOOD

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target

(2015) F. Mussai et al.   BLOOD

Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias

(2015) M. R. Ricciardi et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

(2015) N. Jacque et al.   BLOOD

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia

(2015) B. J. Wouters et al.   BLOOD

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

(2015) Colin A. Flaveny et al.   CANCER CELL

Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids

(2015) A. D. Southam et al.   CANCER RESEARCH

Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death

(2015) E. A. Lee et al.   CANCER RESEARCH

AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow

(2015) Yusuke Saito et al.   Cell Stem Cell

Targeting of cell metabolism in human acute myeloid leukemia - more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?

(2015) Michelle Hauge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

(2015) Jean-Pierre J Issa et al.   LANCET ONCOLOGY

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

(2015) N Daver et al.   LEUKEMIA

Antileukemic Activity of 2-Deoxy-D-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations

(2015) C. Larrue et al.   MOLECULAR CANCER THERAPEUTICS

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia

(2015) Pierre Sujobert et al.   Cell Reports

Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches

(2015) Ângela Fernandes et al.   Oncotarget

HIF-1α and GLUT1 Gene Expression is Associated with Chemoresistance of Acute Myeloid Leukemia

(2014) Kui Song et al.   Asian Pacific Journal of Cancer Prevention

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

(2014) W.-L. Chen et al.   BLOOD

Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance

(2014) Lev M. Kats et al.   Cell Stem Cell

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

(2014) S. Dalva-Aydemir et al.   CLINICAL CANCER RESEARCH

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults

(2014) Heidi D. Klepin et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

(2014) R B Walter et al.   LEUKEMIA

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of mTOR-Dependent Autophagy Sensitizes Leukemic Cells to Cytarabine-Induced Apoptotic Death

(2014) Mihajlo Bosnjak et al.   PLoS One

Growing knowledge of the mTOR signaling network

(2014) Kezhen Huang et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis

(2014) T Liu et al.   Cell Death & Disease

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

(2013) L. Willems et al.   BLOOD

Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia

(2013) Atsushi Hirao et al.   CANCER SCIENCE

Cellular Fatty Acid Metabolism and Cancer

(2013) Erin Currie et al.   Cell Metabolism

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia

(2013) Steven M. Chan et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells

(2013) S Scotland et al.   LEUKEMIA

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output

(2013) Christian C. Dibble et al.   NATURE CELL BIOLOGY

Amino acid signalling upstream of mTOR

(2013) Jenna L. Jewell et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

(2012) Z. Zeng et al.   BLOOD

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Autophagy in tumor suppression and cancer therapy

(2012) Che-Pei Kung et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

(2012) Alberto M Martelli et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy

(2012) W-Y Shi et al.   Cell Death & Disease

The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance

(2011) Monika Mortensen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

(2011) L Willems et al.   LEUKEMIA

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation

(2010) W. C. Chou et al.   BLOOD

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

(2010) A. S. Green et al.   BLOOD

FIP200 is required for the cell-autonomous maintenance of fetal hematopoietic stem cells

(2010) F. Liu et al.   BLOOD

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome

(2010) Patries M. Herst et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The Lkb1 metabolic sensor maintains haematopoietic stem cell survival

(2010) Sushma Gurumurthy et al.   NATURE

Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy

(2009) Paul Nicklin et al.   CELL

The Double-Edged Sword of Autophagy Modulation in Cancer

(2009) E. White et al.   CLINICAL CANCER RESEARCH

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

(2009) S. Park et al.   HAEMATOLOGICA

Cancer genome sequencing: a review

(2009) E. R. Mardis et al.   HUMAN MOLECULAR GENETICS

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Acquired copy number alterations in adult acute myeloid leukemia genomes

(2009) M. J. Walter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Cell Metabolism: Warburg and Beyond

(2008) Peggy P. Hsu et al.   CELL

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

(2008) D. A. Rizzieri et al.   CLINICAL CANCER RESEARCH

Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60ρ0 cells

(2007) Patries M. Herst et al.   LEUKEMIA RESEARCH